TY - JOUR
T1 - Evaluating the Phase II drugs currently under investigation for diabetic neuropathy
AU - Adeghate, Ernest
AU - Fehér, Erzsébet
AU - Kalász, Huba
N1 - Publisher Copyright:
© Informa UK, Ltd.
PY - 2015/1/1
Y1 - 2015/1/1
N2 - Introduction: The worldwide number of patients suffering from diabetes mellitus (DM) is projected to approach 552 million by the year 2030. As diabetic neuropathy (DN) is present in 8% of new diabetic patients at the time of diagnosis and occurs in ∼ 50% of all patients with established DM, the number of patients who will develop painful DN will also increase. The suboptimal efficacies of currently approved drugs have prompted investigators to develop new therapeutic agents for the management of painful DN.Areas covered: In this review, the authors present and elucidate the current status of drugs under investigation for the treatment of painful DN. A short synopsis of currently approved drugs is also given. Literature information and data analysis were retrieved from PubMed, the American Diabetes and Neurological Associations Websites and ClinicalTrials.gov. The keywords used in the search included: DM, DN, painful diabetic neuropathy.Expert opinion: In addition to treating the pain associated with DN, the actual causes of the disease should also be targeted for improved management. It is hoped that drugs which improve vascular blood flow, induce neural regeneration, reduce hyperglycemia, oxidative stress and inflammation can be more effective for the overall treatment of painful DN.
AB - Introduction: The worldwide number of patients suffering from diabetes mellitus (DM) is projected to approach 552 million by the year 2030. As diabetic neuropathy (DN) is present in 8% of new diabetic patients at the time of diagnosis and occurs in ∼ 50% of all patients with established DM, the number of patients who will develop painful DN will also increase. The suboptimal efficacies of currently approved drugs have prompted investigators to develop new therapeutic agents for the management of painful DN.Areas covered: In this review, the authors present and elucidate the current status of drugs under investigation for the treatment of painful DN. A short synopsis of currently approved drugs is also given. Literature information and data analysis were retrieved from PubMed, the American Diabetes and Neurological Associations Websites and ClinicalTrials.gov. The keywords used in the search included: DM, DN, painful diabetic neuropathy.Expert opinion: In addition to treating the pain associated with DN, the actual causes of the disease should also be targeted for improved management. It is hoped that drugs which improve vascular blood flow, induce neural regeneration, reduce hyperglycemia, oxidative stress and inflammation can be more effective for the overall treatment of painful DN.
KW - Clinical trials
KW - Diabetes mellitus
KW - Diabetic neuropathy
KW - Investigation
KW - Phase II drugs
UR - http://www.scopus.com/inward/record.url?scp=84916608404&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84916608404&partnerID=8YFLogxK
U2 - 10.1517/13543784.2014.954033
DO - 10.1517/13543784.2014.954033
M3 - Review article
AN - SCOPUS:84916608404
SN - 1354-3784
VL - 24
SP - 1
EP - 15
JO - Expert Opinion on Investigational Drugs
JF - Expert Opinion on Investigational Drugs
IS - 1
ER -